Sprache auswählen
Claudin-18.1
Claudin-18.1 Produktliste
- Attribut
Protein (4)
- Produktbibliothek
Online (3)In Forschung (1)
- Spezies
Human (4)
- Etikett
- (2)His Tag & Flag Tag (2)
- Marker
Unconjugated (3)Biotin-labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
CL1-H51D3 |  Human | E. coli | Human Claudin-18.1 (1-200) Protein, His,Flag Tag (Detergent) |  |  Vorbestellung | ||
CL1-H52P3 | Human | HEK293 | Human Claudin-18.1 Full Length Protein (VLP) |  | In den Warenkorb legen | ||
CL1-H55D9 | Human | InsectCells | Human Claudin-18.1 Protein, His,Flag Tag (Detergent) |  | | In den Warenkorb legen | |
CL1-H85D3 | Human | InsectCells | Biotinylated Human Claudin-18.1 Protein, His,Flag Tag&Avitag™ (Detergent) |  | | In den Warenkorb legen |
Gesamtmenge4
- 1
Claudin-18.1 Molekülhintergrund
Claudin-18.1 is a tight junction protein predominantly expressed in gastric epithelium, where it maintains barrier integrity and polarity. Its restricted expression pattern makes it a valuable biomarker and therapeutic target. Claudin-18.1-specific antibodies and CAR-T cells are emerging as promising strategies for treating gastric and pancreatic cancers.
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Osemitamab | MSB-018; TST-001 | Phase 3 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd, HJB (Hangzhou) Co Ltd | Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Lung Neoplasms; Gallbladder Neoplasms | Details |
| IBI-343 | IBI-343; IBI343 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms | Details |
| LM-302 | LM-302; TPX-4589; BMS-986476 | Phase 3 Clinical | LaNova Medicines Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Gastrointestinal Neoplasms | Details |
| SYSA-1801 | SYSA-1801; SYSA1801; CPO-102; EO-3021 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms | Details |
| SHR-A-1904 | SHR-A-1904; SHR-A1904 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Lymphangioma, Cystic; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| M-108 | M108; M-108 | Phase 3 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| CMG-901 | CMG-901; CMG901; AZD-0901; AZD0901 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| ASKB-589 | ASKB-589 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd, AskGene Pharma Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
| KD-182 | KD-182 | Phase 2 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Stomach Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen) | AB-011 | Phase 2 Clinical | Kaixing Life Technology (Shanghai) Co Ltd, Carsgen Biomedicine (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| CLDN18.2-TAC T cells Therapy | CLDN-18.2-TAC T cells; CLDN18.2-TAC T cells | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours; Stomach Neoplasms | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal | Details |
| XNW-27011 | XNW-27011 | Phase 2 Clinical | Suzhou Sinovent Pharmaceuticals Co Ltd | Solid tumours; Ovarian Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| IMC-002 (Suzhou Immunofoco) | IMC-002 | Phase 2 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Digestive System Neoplasms | Details |
| LB-4330 | Bis-2; LB-4330 | Phase 2 Clinical | L&L Biopharma Co Ltd | Solid tumours | Details |
| PM-1032 | PM1032; PM-1032 | Phase 2 Clinical | Shanghai Genechem Co Ltd | Neoplasms; Pancreatic Neoplasms | Details |
| PT-886 | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| SKB-315 | SKB-315; SKB315; MK1200; MK-1200 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| ATG-022 | ATG-022; ATN-022 | Phase 2 Clinical | Antengene Corporation Co Ltd | Solid tumours; Stomach Neoplasms | Details |
| QLS-31905 | QLS-31905 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| SOT-102 | SOT-102; SOT102; SO-N102 | Phase 2 Clinical | Sotio Biotech AG | Stomach Neoplasms; Pancreatic Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms | Details |
| Recombinant humanized monoclonal antibody MIL93(Mabworks) | MIL-93 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms | Details |
| RC-118 | RC-118; YH005 ADC | Phase 2 Clinical | RemeGen Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours | Details |
| Satricabtagene autoleucel | CT041; CT-041 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| KD-496 | KD-496(4th); KD-496 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms | Details |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma | Details |
| XKDCT-225 | XKDCT225; XKDCT-225 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Solid tumours | Details |
| [68Ga]Ga-NODAGA-SNA014 | [68Ga]Ga-NODAGA-SNA014 | Phase 1 Clinical | Smartnuclide Biopharma | Pancreatic Neoplasms; Adenocarcinoma | Details |
| HD-004 | HD004; HD-004 | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Solid tumours | Details |
| SPX-102 | SPX-102 | Phase 1 Clinical | Sparx Therapeutics Inc | Neoplasms | Details |
| Cord Blood-Derived CAR-NK Cells therapy (Rongu Biotechnology) | CB CAR-NK182; RG-CLDN18.2 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
| LNF-2007 | LNF2007; LNF-2007 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | Details |
| BL-M05D1 | BL-M05D1; BLM05D1 | Phase 1 Clinical | SystImmune | Solid tumours | Details |
| AHT-102 | AHT102; AHT-102 | Phase 1 Clinical | Solid tumours | Details | |
| AZD-6422 | AZD6422; AZD-6422 | Phase 1 Clinical | Astrazeneca Plc | Gastrointestinal Neoplasms | Details |
| GC-506 | GC506; GC-506 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms | Details |
| 68Ga-PMD22(Peking Union Medical College Hospital) | Phase 1 Clinical | Peking Union Medical College Hospital | Gastrointestinal Neoplasms | Details | |
| AK-132 | AK132; AK-132 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| AHT-101 | AHT-101; AHT101 | Phase 1 Clinical | Solid tumours | Details | |
| TQB-2103 | TQB2103; TQB-2103 | Phase 1 Clinical | Neoplasms | Details | |
| BIO-008 | BIO-008 | Phase 1 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd | Solid tumours | Details |
| BA-1301 | BA-1301; BA1301 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| RB-0011 | RB0011; RB-0011 | Phase 1 Clinical | Ruiyang (Suzhou) Biological Technology Co Ltd | Solid tumours | Details |
| LB-1904 | LB-1904 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Stomach Neoplasms | Details |
| Ori-C-613 | Ori-C-613; OriC-613; Ori-C613 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| CT-048 | CT-048; KJ-C1807; KJ-C-1807 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| HEC-016 | HEC-016 | Phase 1 Clinical | People Hospital Of Luohu,Shenzhen | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| PM-3023 | PM-3023 | Phase 1 Clinical | Solid tumours | Details | |
| RD-07 | RD-07 | Phase 1 Clinical | Peking University | Solid tumours | Details |
| IBI-345 | IBI-345 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| JS-107 | JS-107; JS107 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Pancreatic Neoplasms | Details |
| TORL-2-307-MAB | TORL-2-307-MAB | Phase 1 Clinical | Torl Biotherapeutics LLC | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| TORL-2-307-ADC | TORL-2-307-ADC | Phase 1 Clinical | Torl Biotherapeutics LLC | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| BC-008 | BC-008 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
| BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
| DR-30303 | DR30303 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
| SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
| BA-1105 | BA1105; BA-1105 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
| CLDN 18.2 CAR-T cell therapy (Shanghai Longyao) | LY-011 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
| NBL-015 | NBL-015 | Phase 1 Clinical | Shanghai Xinshi Biological Medicine Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| IBI-360 | IBI-360 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| Givastomig | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis | Details |
| QL-1779 | QL-1779; QL1779 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LM-102 | LM-102 | Phase 1 Clinical | LaNova Medicines Ltd | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
| HBM-1029 | HBM-1029; HBM1029 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms | Details |
| LCAR-C18S CAR-T cell therapy (Legend) | LB-1908; LCAR-C18S; LCAR-C-18-S | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details |
| XKDCT-086 | XKDCT086; XKDCT-086 | Clinical | The Affiliated Hospital Of Qingdao University | Stomach Neoplasms | Details |
| CLDN18.2 UCAR-T cell therapy | CLDN18.2 UCAR-T | Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Stomach Neoplasms | Details |
| 124I-18B10 | 124I-18B10; 124-I-18-B-10 | Clinical | Transcenta Holding Ltd, Beijing Cancer Hospital | Gastrointestinal Neoplasms | Details |
| CTB-001(Nanjing Bioheng) | CTB-001; CTB001 | Clinical | Nanjing Bioheng Biotech Co Ltd | Stomach Neoplasms; Pancreatic Neoplasms | Details |
| 89Zr-NY005 | 89Zr-NY005 | Clinical | Wuxi Nuoyu Pharmaceutical Technology Co Ltd | Solid tumours; Stomach Neoplasms | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Zolbetuximab | GC-182; iMAB-362; IMAB-362 | Approved | Ganymed | Vyloy, VYLOY, 威络益 | Japan | Stomach Neoplasms | Astellas Pharma Inc | 2024-03-26 | Solid tumours; Lymphangioma, Cystic; Stomach Neoplasms; Pain; Esophageal Neoplasms; Pancreatic Neoplasms; Adenocarcinoma | Details |
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main